XKRX
302440
Market cap2.67bUSD
Jul 25, Last price
47,200.00KRW
1D
-0.53%
1Q
16.69%
IPO
-71.65%
Name
SK Bioscience Co Ltd
Chart & Performance
Profile
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | |||||||
Revenues | 267,545,049 -27.59% | 369,505,556 -19.10% | 456,725,871 -50.84% | ||||
Cost of revenue | 348,820,259 | 338,772,125 | 302,391,700 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (81,275,210) | 30,733,431 | 154,334,171 | ||||
NOPBT Margin | 8.32% | 33.79% | |||||
Operating Taxes | (38,989,758) | (14,990,492) | 19,281,233 | ||||
Tax Rate | 12.49% | ||||||
NOPAT | (42,285,452) | 45,723,923 | 135,052,939 | ||||
Net income | (53,881,199) -341.43% | 22,317,719 -81.77% | 122,451,950 -65.52% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 75,680,234 | 397,599 | 2,617,946 | ||||
BB yield | -1.95% | -0.01% | -0.05% | ||||
Debt | |||||||
Debt current | 6,956,508 | 8,137,402 | 95,792,981 | ||||
Long-term debt | 395,339,753 | 33,009,655 | 47,320,949 | ||||
Deferred revenue | 51,026,374 | ||||||
Other long-term liabilities | 1,710,993 | 527,842 | 2,648,749 | ||||
Net debt | 66,074,809 | (1,275,723,547) | (87,318,302) | ||||
Cash flow | |||||||
Cash from operating activities | (128,019,869) | 29,346,361 | (124,958,284) | ||||
CAPEX | (164,413,439) | (50,295,489) | (76,489,443) | ||||
Cash from investing activities | 53,563,803 | (45,278,721) | 272,646,505 | ||||
Cash from financing activities | 252,479,228 | (89,582,616) | (19,867,162) | ||||
FCF | (830,895,439) | 41,501,495 | 44,335,516 | ||||
Balance | |||||||
Cash | 1,158,108,158 | 1,274,141,241 | 1,480,805,573 | ||||
Long term investments | (821,886,706) | 42,729,362 | (1,250,373,341) | ||||
Excess cash | 322,844,199 | 1,298,395,326 | 207,595,939 | ||||
Stockholders' equity | 758,817,858 | 543,399,377 | 581,693,865 | ||||
Invested Capital | 1,925,272,141 | 1,181,557,309 | 1,629,875,111 | ||||
ROIC | 3.25% | 8.57% | |||||
ROCE | 1.78% | 8.40% | |||||
EV | |||||||
Common stock shares outstanding | 76,828 | 77,014 | 77,021 | ||||
Price | 50,400.00 -30.00% | 72,000.00 -2.04% | 73,500.00 -67.33% | ||||
Market cap | 3,872,118,298 -30.17% | 5,544,987,408 -2.05% | 5,661,079,736 -67.11% | ||||
EV | 4,158,080,058 | 4,269,263,861 | 5,573,761,433 | ||||
EBITDA | (32,049,976) | 65,498,134 | 181,570,580 | ||||
EV/EBITDA | 65.18 | 30.70 | |||||
Interest | 3,684,910 | 1,398,139 | 2,460,940 | ||||
Interest/NOPBT | 4.55% | 1.59% |